ARVADA, CO--(Marketwire - July 23, 2009) - GeneThera, Inc. (PINKSHEETS: GTHR) today
announced it has retained Pfeiffer High Investor Relations, Inc. to develop
and implement a comprehensive investor relations program.
Dr. Tony Milici, founder and CEO of GeneThera, said, "We are nearing the
achievement of multiple strategic milestones, including the launch of a
pivotal marketing trial for our Johne's disease testing application. It is
imperative that our story and accomplishments are effectively communicated
by an organization equipped to address the many facets of a successful
investor relations program. We are confident we have found that
organization in Pfeiffer High."
Geoff High, principal of Pfeiffer High Investor Relations, said,
"GeneThera's focus on the development of testing and prevention
applications for animal-to-human 'crossover' diseases could have
substantial long-term implications for the global food and agricultural
industries. We look forward to helping GeneThera broadly expand its
audience and will work to communicate its story to retail and institutional
investors, as well as the financial media."
About GeneThera, Inc.
GeneThera, Inc. is a biotechnology company focused on the development of
molecular assays. The Company is currently in the process of developing
therapeutic vaccines for the detection and prevention of food contaminating
pathogens, veterinary diseases, and diseases affecting human health. More
information about the Company can be found at: http://www.genethera.net.
About Pfeiffer High Investor Relations, Inc.
Pfeiffer High is a full-service investor relations firm based in Denver.
Since 1982 it has been helping public companies maximize shareholder value
by implementing comprehensive investor relations programs that raise
awareness among buy- and sell-side analysts, institutional portfolio
managers, brokers, individual investors and the financial media.
Safe Harbor Statement
Certain statements and information included in this press release
constitute "forward-looking statements" within the meaning of the Federal
Private Securities Litigation Reform Act of 1995, including statements
regarding our forthcoming achievement of multiple strategic milestones, the
launch of a pivotal marketing trial for our Johne's disease testing
applications, the potential that our focus on the testing and prevention of
animal-to-human "crossover" diseases could have substantial long-term
implications for the global food and agricultural industries and Pfeiffer
High Investor Relations' ability to effectively communicate our story and
progress to retail and institutional investors, as well as the financial
Forward-looking statements involve known and unknown risks and
uncertainties, which may cause the Company's actual results in future
periods to differ materially from forecasted results. Factors that could
cause or contribute to such differences include, but are not limited to,
our ability to raise capital, our ability to execute our business strategy
in a very competitive environment, our degree of financial leverage, risks
relating to rapidly developing technology, regulatory considerations, risks
related to international economies, risks related to market acceptance and
demand for our products and services, the impact of competitive services
and pricing, and other risks referenced from time to time in our SEC
filings. All subsequent written and oral forward-looking statements
attributable to us, or anyone acting on our behalf, are expressly qualified
in their entirety by these cautionary statements. We do not undertake any
obligations to publicly release any revisions to any forward-looking
statements to reflect events or circumstances after the date of this press
release or to reflect unanticipated events that may occur.